A Case of Hyperacute Severe Thrombocytopenia Occurring Less than 24 Hours after Intravenous Tirofiban Infusion.

about

A Case of Hyperacute Severe Thrombocytopenia Occurring Less than 24 Hours after Intravenous Tirofiban Infusion.

Item

http://www.wikidata.org/entity/Q55442994

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

A Case of Hyperacute Severe Th ...... ntravenous Tirofiban Infusion.

@en

A Case of Hyperacute Severe Th ...... ntravenous Tirofiban Infusion.

@nl

type

Item

label

A Case of Hyperacute Severe Th ...... ntravenous Tirofiban Infusion.

@en

A Case of Hyperacute Severe Th ...... ntravenous Tirofiban Infusion.

@nl

prefLabel

A Case of Hyperacute Severe Th ...... ntravenous Tirofiban Infusion.

@en

A Case of Hyperacute Severe Th ...... ntravenous Tirofiban Infusion.

@nl

P1476

A Case of Hyperacute Severe Th ...... Intravenous Tirofiban Infusion

@en

P2093

Bernard Topi

http://www.w3.org/2001/XMLSchema#string

Nitin Sabharwal

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia

Comparative pharmacology of GP IIb/IIIa antagonists

Abciximab readministration: results of the ReoPro Readministration Registry

Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells

A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors.

Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.

Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.

Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells.

Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated.

Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.

P304

4357981

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1155/2018/4357981

http://www.w3.org/2001/XMLSchema#string

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

Vinod Namana

Vineet Meghrajani

Moustafa O Elsheshtawy

P577

2018-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29977628

http://www.w3.org/2001/XMLSchema#string

P921

thrombocytopenia

P932

5994276

http://www.w3.org/2001/XMLSchema#string